-
141
-
142
-
143
-
144
-
145
Donor Cell-Derived Myelodysplastic Syndrome Following Allogenic Peripheral Blood Stem Cell Transplant
Published 2023-04-01Get full text
Article -
146
-
147
Adjuvant treatment for high risk melanoma. Where are we now?
Published 2011-12-01Get full text
Article -
148
Adjuvant treatment for high risk melanoma. Where are we now?
Published 2011-12-01Get full text
Article -
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
Advances in the treatment of soft tissue sarcoma: focus on eribulin
Published 2018-02-01“…Panagiotis Koliou,1,* Vasilios Karavasilis,1,* Maria Theochari,2 Seth M Pollack,3 Robin L Jones,4 Khin Thway4 1The London Sarcoma Service, University College London Hospital, London, UK; 2Hippokration Hospital, University of Athens, Athens, Greece; 3Division of Oncology, University of Washington, Seattle, WA, USA; 4Royal Marsden Hospital, London, UK *These authors contributed equally to this work Abstract: Eribulin mesylate is a synthetic derivative of halichondrin B isolated from a marine sponge. …”
Get full text
Article -
158
Splenic marginal zone lymphoma: a review of the clinical presentation, pathology, molecular biology, and management
Published 2014-07-01“…Larissa Sena Teixeira Mendes,1 Ming-Qing Du,2 Estella Matutes,3 Andrew Wotherspoon11Histopathology Department, Royal Marsden Hospital, London, UK; 2Molecular Malignancy Laboratory and Department of Histopathology, University Hospital NHS Foundation Trust/Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK; 3Hematopathology Unit, Hospital Clinic, Barcelona University, Barcelona, Spain Abstract: Splenic marginal zone lymphoma is a distinct low grade B-cell lymphoma primarily occurring in the spleen and separate from nodal marginal zone lymphoma and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. …”
Get full text
Article -
159
-
160